The metabolism of cancer cells is different from that of healthy cells. That leads to the production of more lactic acid in cancer cells. Cancer cells quickly pump hydrogen out of themselves to survive. As a result, an acidic shell forms outside the cancer cell. This shell reduces the entry of many cancer drugs, reduces their effectiveness, and weakens the immune system.
Several in vitro and in vivo studies reported that neutralization of the acidic tumor microenvironmentby alkalizing agents, such as bicarbonate, resulted in the suppression of cancer progression and a potential benefit for anti-cancer drug responses. In clinical settings, alkalizing effects were achieved not only by alkalizing agents, but also by a following a particular diet. An epidemiological study demonstrated that more fruits and vegetables and less meat and dairy products are associated with an increase in urine pH, which may reflect the alkalizing effect on the body.
Giving a high dose of sodium bicarbonate through the bloodstream and giving drugs that block the pumps that pump acid out of cancer cells can break the acidic shell around the cancer cell and provide additional benefits to cancer treatment. It has been shown that the killing effect of various cancer drugs is increased with alkaline cancer treatments.
Altering the acidic pH environment around the tumor cell to a more alkaline pH increases the effectiveness of anticancer immunotherapy drugs.
In a clinical study conducted in patients with metastatic pancreatic cancer, it was shown that with the addition of alkaline treatment to standard medical treatment, the life expectancy of patients was longer than that of patients who did not receive alkaline treatment (alkali treatment plus medical treatment average survival time was 15.4 months versus only medical treatment 10, 8 months).
In our clinic, modern personalized medical cancer treatment, metabolic sugar-controlled chemotherapy (insulin potentiated chemotherapy) and alkaline cancer treatment are performed.

Reference:
1. Hamaguchi R, Front Oncol. 2022 Sep 14;12:1003588.
2. Pilon-Thomas S, Cancer Res. 2016;76(6):1381-90. 
3. Koltai T. Onco Targets Ther. 2016;9:6343-6360. 
4. De Milito A, Future Oncol. 2005;1(6):779-86.
5. Hamaguchi R,  In Vivo. 2020 Sep-Oct;34(5):2623-2629.